TESARO price target raised to $51 from $42 at Citigroup Citigroup raised its price target for TESARO shares to $51 citing the company's expanded immuno-oncology pipeline following its license agreement with AnaptysBio. Citi keeps a Buy rating on the stock, saying shares remain compelling.
News For TSRO From The Last 14 Days
Check below for free stories on TSRO the last two weeks.
TESARO submits rolapitant NDA to FDA TESARO announced that it has submitted the New Drug Application, or NDA, for oral rolapitant to the FDA. Rolapitant is an investigational neurokinin-1 receptor antagonist developed for the prevention of chemotherapy-induced nausea and vomiting.